
ECL AI Price Prediction
Track ECL's AI-powered predictions, market trends, and investment insights.
You don't hold ECL in your mock portfolio yet.
Track ECL's AI-powered predictions, market trends, and investment insights.
You don't hold ECL in your mock portfolio yet.
Upgrade to see the full Evidence Stack
What Changed, Why Now, and Risk Flags — available on the Investor plan and above
Get StartedThe given fundamentals (PE of 34.59 and EPS of 7.40) suggest Ecolab is a profitable, mature business that the market currently values at a premium multiple. However, without explicit revenue and margin trend data, it is difficult to argue for a clearly bullish or bearish stance solely on fundamentals. The valuation implies investors expect steady earnings growth, but not at a deep-value price.
At $256.00, Ecolab trades meaningfully below its 200-day moving average of $271.59, which is a negative technical signal suggesting a downtrend or at least technical weakness. The modest 0.2% gain over the last month indicates a lack of strong positive momentum. Combined, these signals lean bearish from a technical perspective, even if the longer-term fundamental story may remain intact.
Alternative data for Ecolab is mixed: web traffic is sizable, but job openings have fallen sharply month over month, which may signal a hiring pause or efficiency focus. Social media presence is broad and generally growing modestly across most platforms, particularly LinkedIn, which is relevant for a B2B-focused company. Overall, these signals suggest a stable to slightly positive business and brand presence, but not a strong near-term growth inflection.
Ecolab appears fundamentally sound and profitable, with the market assigning it a premium valuation, but the stock is currently trading below its 200-day moving average and shows only marginal recent price appreciation. Alternative data suggests a stable, well-established business with modestly growing professional and social reach, offset by a notable drop in job postings that clouds the near-term growth signal. Overall, the balance of fundamentals, technicals, and alternative data supports a neutral stance on the stock at current levels.
Our AI Score rates companies on a scale from 0 to 10, based on alternative data points such as web traffic, app downloads, and job postings — combined with financial health indicators and technical signals.



Ecolab Schedules Webcast of Industry Conference for June 2, 2026

Ecolab Delivers Strong Performance and Impact
Ecolab (ECL) is currently trading at $255.67 on the NYSE, reflecting a marginal single-day decline of 0.2% with daily volume of 866,688 shares. The company commands a substantial market capitalization of $72.0 billion, reinforcing its position as a dominant force in the specialty chemicals sector. Ecolab's diversified business spans water treatment, hygiene, and infection prevention across industrial, institutional, and healthcare end markets globally. This breadth of exposure provides revenue resilience, though it also means the stock's performance is tightly linked to broader industrial activity and institutional spending cycles.
TrendEdge's AI model assigns Ecolab a score of 6 out of 10, reflecting a moderately constructive but not decisively bullish outlook. The score suggests that while Ecolab's fundamental positioning is solid — backed by its $72B market cap and diversified segment structure — there are insufficient near-term momentum signals to push the rating higher. With 1,000 active job postings, the company is clearly investing in operational capacity, which can be an early indicator of organic growth intentions. However, limited social sentiment data and low Reddit activity of just 2 mentions indicate the stock is not currently attracting speculative retail interest.
Looking ahead, investors should monitor Ecolab's ability to expand margins across its Global Industrial and Healthcare & Life Sciences segments, particularly as water treatment and hygiene solutions face both regulatory tailwinds and cost pressures. The 1,000 active job postings signal potential capacity buildup, which could pressure near-term earnings if revenue growth lags hiring. Macro sensitivity to industrial output and institutional budgets remains a key risk. Any acceleration in pricing power or new contract wins in life sciences could serve as meaningful upside catalysts for ECL in 2026.
Unlock comprehensive alternative data signals to make better investment decisions
TrendEdge provides tools and data for research and educational purposes only and does not provide investment advice or personal recommendations.
Web Traffic
822,728
Twitter Followers
22,272
Instagram Followers
38,566
YouTube Subscribers
26,100
LinkedIn Followers
913,001
Job Postings
1,000
LinkedIn Employees
48,909
News Mentions
0
Key Metrics